Your browser doesn't support javascript.
loading
Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry.
Sanz-Garcia, Enrique; Brown, Samantha; Lavery, Jessica A; Weiss, Jessica; Fuchs, Hannah E; Newcomb, Ashley; Postle, Asha; Warner, Jeremy L; LeNoue-Newton, Michele L; Sweeney, Shawn M; Pillai, Shirin; Yu, Celeste; Nichols, Chelsea; Mastrogiacomo, Brooke; Kundra, Ritika; Schultz, Nikolaus; Kehl, Kenneth L; Riely, Gregory J; Schrag, Deborah; Govindarajan, Anand; Panageas, Katherine S; Bedard, Philippe L.
Affiliation
  • Sanz-Garcia E; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Department of Medicine, University of Toronto, Ontario, Canada.
  • Brown S; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Lavery JA; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Weiss J; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Department of Medicine, University of Toronto, Ontario, Canada.
  • Fuchs HE; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Newcomb A; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Postle A; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Warner JL; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • LeNoue-Newton ML; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • Sweeney SM; American Association of Cancer Research, Philadelphia, Pennsylvania.
  • Pillai S; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yu C; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Department of Medicine, University of Toronto, Ontario, Canada.
  • Nichols C; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mastrogiacomo B; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kundra R; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schultz N; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kehl KL; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Riely GJ; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schrag D; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Govindarajan A; Sinai Health System, Toronto, Ontario, Canada.
  • Panageas KS; Department of Surgery, University of Toronto, Ontario, Canada.
  • Bedard PL; Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Res Commun ; 4(2): 475-486, 2024 02 20.
Article in En | MEDLINE | ID: mdl-38329392
ABSTRACT
Peritoneal metastases (PM) are common in metastatic colorectal cancer (mCRC). We aimed to characterize patients with mCRC and PM from a clinical and molecular perspective using the American Association of Cancer Research Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC) registry. Patients' tumor samples underwent targeted next-generation sequencing. Clinical characteristics and treatment outcomes were collected retrospectively. Overall survival (OS) from advanced disease and progression-free survival (PFS) from start of cancer-directed drug regimen were estimated and adjusted for the left truncation bias. A total of 1,281 patients were analyzed, 244 (19%) had PM at time of advanced disease. PM were associated with female sex [OR 1.67; 95% confidence interval (CI) 1.11-2.54; P = 0.014] and higher histologic grade (OR 1.72; 95% CI 1.08-2.71; P = 0.022), while rectal primary tumors were less frequent in patients with PM (OR 0.51; 95% CI 0.29-0.88; P < 0.001). APC occurred less frequently in patients with PM (N = 151, 64% vs. N = 788, 79%) while MED12 alterations occurred more frequently in patients with PM (N = 20, 10% vs. N = 32, 4%); differences in MED12 were not significant when restricting to oncogenic and likely oncogenic variants according to OncoKB. Patients with PM had worse OS (HR 1.45; 95% CI 1.16-1.81) after adjustment for independently significant clinical and genomic predictors. PFS from initiation of first-line treatment did not differ by presence of PM. In conclusion, PM were more frequent in females and right-sided primary tumors. Differences in frequencies of MED12 and APC alterations were identified between patients with and without PM. PM were associated with shorter OS but not with PFS from first-line treatment.

SIGNIFICANCE:

Utilizing the GENIE BPC registry, this study found that PM in patients with colorectal cancer occur more frequently in females and right-sided primary tumors and are associated with worse OS. In addition, we found a lower frequency of APC alterations and a higher frequency in MED12 alterations in patients with PM.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peritoneal Neoplasms / Rectal Neoplasms / Colorectal Neoplasms / Colonic Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Cancer Res Commun Year: 2024 Document type: Article Affiliation country: Canada Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peritoneal Neoplasms / Rectal Neoplasms / Colorectal Neoplasms / Colonic Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Cancer Res Commun Year: 2024 Document type: Article Affiliation country: Canada Country of publication: United States